Study S000503

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06388187
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 300
Start: 2024-06-24
Primary completion: 2026-04-22
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1298-3451; OTHER:2023-509273-24; NIH:2023

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]
Achievement of ≥5% weight reduction [From baseline (week 0) to end of treatment (week 68)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.